CO2024015763A2 - Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor - Google Patents
Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolorInfo
- Publication number
- CO2024015763A2 CO2024015763A2 CONC2024/0015763A CO2024015763A CO2024015763A2 CO 2024015763 A2 CO2024015763 A2 CO 2024015763A2 CO 2024015763 A CO2024015763 A CO 2024015763A CO 2024015763 A2 CO2024015763 A2 CO 2024015763A2
- Authority
- CO
- Colombia
- Prior art keywords
- voltage
- treatment
- pain
- inhibitors
- bicyclic heterocyclic
- Prior art date
Links
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 title 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 title 1
- -1 activated sodium bicyclic heterocyclic amide Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211024240 | 2022-04-25 | ||
| IN202311013223 | 2023-02-27 | ||
| PCT/US2023/019879 WO2023211990A1 (en) | 2022-04-25 | 2023-04-25 | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024015763A2 true CO2024015763A2 (es) | 2025-02-13 |
Family
ID=86469337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0015763A CO2024015763A2 (es) | 2022-04-25 | 2024-11-20 | Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4514789A1 (https=) |
| JP (1) | JP2025516005A (https=) |
| KR (1) | KR20250006217A (https=) |
| CN (1) | CN119585247A (https=) |
| AU (1) | AU2023263309A1 (https=) |
| CA (1) | CA3256486A1 (https=) |
| CL (1) | CL2024003258A1 (https=) |
| CO (1) | CO2024015763A2 (https=) |
| CR (1) | CR20240512A (https=) |
| DO (1) | DOP2024000215A (https=) |
| GE (1) | GEAP202516637A (https=) |
| IL (1) | IL316433A (https=) |
| JO (1) | JOP20240238A1 (https=) |
| MX (1) | MX2024013065A (https=) |
| PE (1) | PE20251183A1 (https=) |
| WO (1) | WO2023211990A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025529613A (ja) | 2022-08-12 | 2025-09-09 | グアンジョウ フェルミオン テクノロジー カンパニー リミテッド | 電位開口型ナトリウムチャネル阻害剤としての化合物 |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| TW202547515A (zh) * | 2024-04-30 | 2025-12-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 芳香環類化合物、其製備方法及其在醫藥上的應用 |
| WO2026001999A1 (zh) * | 2024-06-25 | 2026-01-02 | 江苏恒瑞医药股份有限公司 | 芳香环类化合物、其制备方法及其在医药上的应用 |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3211934A1 (de) * | 1982-03-31 | 1983-10-13 | Hoechst Ag, 6230 Frankfurt | Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2004034985A2 (en) * | 2002-10-16 | 2004-04-29 | Smithkline Beecham Corporation | Chemical compounds |
| ES2377988T3 (es) * | 2005-11-14 | 2012-04-03 | Vertex Pharmaceuticals, Inc. | Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje |
| WO2008135830A1 (en) | 2007-05-03 | 2008-11-13 | Pfizer Limited | N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| EA023375B1 (ru) | 2011-10-26 | 2016-05-31 | Пфайзер Лимитед | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов |
| WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
| AU2014212431B2 (en) | 2013-01-31 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| MA41051B1 (fr) * | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| EP3873893A1 (en) | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020092187A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2020261114A1 (en) | 2019-06-27 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
| WO2021032074A1 (zh) | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| JP2023530319A (ja) | 2020-06-17 | 2023-07-14 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド |
| BR112022024476A2 (pt) | 2020-06-17 | 2022-12-27 | Merck Sharp & Dohme Llc | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 |
| GEP20257750B (en) | 2020-06-17 | 2025-03-25 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| WO2022121805A1 (zh) * | 2020-12-07 | 2022-06-16 | 成都康弘药业集团股份有限公司 | 作为Nav1.8抑制剂的并环化合物及其用途 |
-
2023
- 2023-04-25 IL IL316433A patent/IL316433A/en unknown
- 2023-04-25 GE GEAP202516637A patent/GEAP202516637A/en unknown
- 2023-04-25 WO PCT/US2023/019879 patent/WO2023211990A1/en not_active Ceased
- 2023-04-25 CR CR20240512A patent/CR20240512A/es unknown
- 2023-04-25 JP JP2024563159A patent/JP2025516005A/ja active Pending
- 2023-04-25 EP EP23725500.5A patent/EP4514789A1/en active Pending
- 2023-04-25 PE PE2024002316A patent/PE20251183A1/es unknown
- 2023-04-25 CN CN202380049371.6A patent/CN119585247A/zh active Pending
- 2023-04-25 CA CA3256486A patent/CA3256486A1/en active Pending
- 2023-04-25 KR KR1020247039008A patent/KR20250006217A/ko active Pending
- 2023-04-25 AU AU2023263309A patent/AU2023263309A1/en active Pending
-
2024
- 2024-10-22 JO JOJO/P/2024/0238A patent/JOP20240238A1/ar unknown
- 2024-10-23 MX MX2024013065A patent/MX2024013065A/es unknown
- 2024-10-24 DO DO2024000215A patent/DOP2024000215A/es unknown
- 2024-10-25 CL CL2024003258A patent/CL2024003258A1/es unknown
- 2024-11-20 CO CONC2024/0015763A patent/CO2024015763A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240512A (es) | 2025-03-03 |
| EP4514789A1 (en) | 2025-03-05 |
| IL316433A (en) | 2024-12-01 |
| JOP20240238A1 (ar) | 2024-10-22 |
| AU2023263309A1 (en) | 2024-12-05 |
| CA3256486A1 (en) | 2023-11-02 |
| GEAP202516637A (en) | 2025-03-25 |
| WO2023211990A1 (en) | 2023-11-02 |
| DOP2024000215A (es) | 2025-04-30 |
| CL2024003258A1 (es) | 2025-02-14 |
| MX2024013065A (es) | 2024-12-06 |
| JP2025516005A (ja) | 2025-05-23 |
| KR20250006217A (ko) | 2025-01-10 |
| CN119585247A (zh) | 2025-03-07 |
| PE20251183A1 (es) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024015763A2 (es) | Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor | |
| MX2023001741A (es) | Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor. | |
| CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| MX2021013679A (es) | Compuestos antivirales que contienen nitrilo. | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| DOP2022000047A (es) | Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones | |
| MX2019003492A (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostericos negativos de mg1ur2, composiciones y su uso. | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| CO2025007108A2 (es) | Compuestos novedosos como moduladores de la inhibición de nlrp3 | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CR20250537A (es) | Agonistas de trem2 | |
| MX2021009584A (es) | Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih). | |
| AR134196A1 (es) | Derivados de amidas heteroarílicas como inhibidores de los canales de sodio | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina | |
| CO2025013436A2 (es) | Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos | |
| CR20250543A (es) | Derivados de triazina como inhibidores del nlrp3 | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| DOP2024000240A (es) | Antagonistas de at2r y usos de estos | |
| AR131345A1 (es) | SULFOXIMINAS COMO INHIBIDORES DE NaV1.8 | |
| CL2025002072A1 (es) | Inhibidores de prmt5–mta. | |
| CR20240481A (es) | DERIVADOS DE PIRROLIDINONA COMO INHIBIDORES DE QUINASA INDUCTORA DE NF-kB |